OTCMKTS:CNBX

Cannabics Pharmaceuticals Competitors

$0.25
-0.03 (-10.71 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.25
Now: $0.25
$0.30
50-Day Range
$0.24
MA: $0.36
$0.52
52-Week Range
$0.14
Now: $0.25
$0.60
Volume546,355 shs
Average Volume475,271 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Cannabics Pharmaceuticals (OTCMKTS:CNBX) Vs. IIPR, GRWG, XXII, KSHB, NSAV, and TRTC

Should you be buying CNBX stock or one of its competitors? Companies in the sub-industry of "cannabis" are considered alternatives and competitors to Cannabics Pharmaceuticals, including Innovative Industrial Properties (IIPR), GrowGeneration (GRWG), 22nd Century Group (XXII), KushCo (KSHB), NSAV (NSAV), and Terra Tech (TRTC).

Cannabics Pharmaceuticals (OTCMKTS:CNBX) and Innovative Industrial Properties (NYSE:IIPR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Valuation and Earnings

This table compares Cannabics Pharmaceuticals and Innovative Industrial Properties' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cannabics PharmaceuticalsN/AN/AN/AN/AN/A
Innovative Industrial Properties$44.67 million101.23$23.48 million$3.2757.80

Innovative Industrial Properties has higher revenue and earnings than Cannabics Pharmaceuticals.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Cannabics Pharmaceuticals and Innovative Industrial Properties, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cannabics Pharmaceuticals0000N/A
Innovative Industrial Properties02502.71

Innovative Industrial Properties has a consensus target price of $192.4286, indicating a potential upside of 1.82%. Given Innovative Industrial Properties' higher probable upside, analysts clearly believe Innovative Industrial Properties is more favorable than Cannabics Pharmaceuticals.

Institutional & Insider Ownership

74.9% of Innovative Industrial Properties shares are owned by institutional investors. 2.9% of Innovative Industrial Properties shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Cannabics Pharmaceuticals and Innovative Industrial Properties' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cannabics PharmaceuticalsN/AN/AN/A
Innovative Industrial Properties55.71%6.05%4.82%

Summary

Innovative Industrial Properties beats Cannabics Pharmaceuticals on 8 of the 8 factors compared between the two stocks.

GrowGeneration (NASDAQ:GRWG) and Cannabics Pharmaceuticals (OTCMKTS:CNBX) are both basic materials companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, risk, earnings, valuation, institutional ownership and dividends.

Insider & Institutional Ownership

51.3% of GrowGeneration shares are held by institutional investors. 13.6% of GrowGeneration shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares GrowGeneration and Cannabics Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GrowGeneration2.14%4.68%3.53%
Cannabics PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for GrowGeneration and Cannabics Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GrowGeneration03502.63
Cannabics Pharmaceuticals0000N/A

GrowGeneration currently has a consensus price target of $49.5714, indicating a potential downside of 8.24%. Given GrowGeneration's higher possible upside, equities research analysts clearly believe GrowGeneration is more favorable than Cannabics Pharmaceuticals.

Earnings and Valuation

This table compares GrowGeneration and Cannabics Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GrowGeneration$79 million39.97$1.88 million$0.10540.20
Cannabics PharmaceuticalsN/AN/AN/AN/AN/A

GrowGeneration has higher revenue and earnings than Cannabics Pharmaceuticals.

Summary

GrowGeneration beats Cannabics Pharmaceuticals on 8 of the 8 factors compared between the two stocks.

Cannabics Pharmaceuticals (OTCMKTS:CNBX) and 22nd Century Group (NYSEAMERICAN:XXII) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Analyst Recommendations

This is a breakdown of current recommendations for Cannabics Pharmaceuticals and 22nd Century Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cannabics Pharmaceuticals0000N/A
22nd Century Group00103.00

Earnings & Valuation

This table compares Cannabics Pharmaceuticals and 22nd Century Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cannabics PharmaceuticalsN/AN/AN/AN/AN/A
22nd Century GroupN/AN/AN/AN/AN/A

Profitability

This table compares Cannabics Pharmaceuticals and 22nd Century Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cannabics PharmaceuticalsN/AN/AN/A
22nd Century GroupN/AN/AN/A

Summary

22nd Century Group beats Cannabics Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

KushCo (OTCMKTS:KSHB) and Cannabics Pharmaceuticals (OTCMKTS:CNBX) are both multi-sector conglomerates companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Insider and Institutional Ownership

0.0% of KushCo shares are held by institutional investors. 17.3% of KushCo shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for KushCo and Cannabics Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
KushCo01302.75
Cannabics Pharmaceuticals0000N/A

KushCo presently has a consensus price target of $1.8750, indicating a potential upside of 45.35%. Given KushCo's higher possible upside, analysts clearly believe KushCo is more favorable than Cannabics Pharmaceuticals.

Earnings and Valuation

This table compares KushCo and Cannabics Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KushCo$113.84 million1.80$-77,660,000.00($0.68)-1.90
Cannabics PharmaceuticalsN/AN/AN/AN/AN/A

Cannabics Pharmaceuticals has lower revenue, but higher earnings than KushCo.

Profitability

This table compares KushCo and Cannabics Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
KushCo-65.89%-47.95%-31.39%
Cannabics PharmaceuticalsN/AN/AN/A

Summary

KushCo beats Cannabics Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

NSAV (OTCMKTS:NSAV) and Cannabics Pharmaceuticals (OTCMKTS:CNBX) are both computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Valuation & Earnings

This table compares NSAV and Cannabics Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NSAVN/AN/AN/AN/AN/A
Cannabics PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for NSAV and Cannabics Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NSAV0000N/A
Cannabics Pharmaceuticals0000N/A

Profitability

This table compares NSAV and Cannabics Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NSAVN/AN/AN/A
Cannabics PharmaceuticalsN/AN/AN/A

Terra Tech (OTCMKTS:TRTC) and Cannabics Pharmaceuticals (OTCMKTS:CNBX) are both industrial products companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Profitability

This table compares Terra Tech and Cannabics Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Terra Tech-261.88%-110.38%-62.41%
Cannabics PharmaceuticalsN/AN/AN/A

Earnings and Valuation

This table compares Terra Tech and Cannabics Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Terra Tech$28.05 million2.25$-46,930,000.00N/AN/A
Cannabics PharmaceuticalsN/AN/AN/AN/AN/A

Cannabics Pharmaceuticals has lower revenue, but higher earnings than Terra Tech.

Insider & Institutional Ownership

0.1% of Terra Tech shares are held by institutional investors. 6.7% of Terra Tech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for Terra Tech and Cannabics Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Terra Tech0000N/A
Cannabics Pharmaceuticals0000N/A


Cannabics Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Innovative Industrial Properties logo
IIPR
Innovative Industrial Properties
1.8$188.99-2.5%$4.52 billion$44.67 million61.16
GrowGeneration logo
GRWG
GrowGeneration
1.7$54.02-2.3%$3.16 billion$79 million1,080.62Analyst Revision
22nd Century Group logo
XXII
22nd Century Group
0.9$3.61-2.5%$550.16 millionN/A0.00
KushCo logo
KSHB
KushCo
1.3$1.29-3.1%$204.89 million$113.84 million-2.15Earnings Announcement
News Coverage
Gap Up
NSAV
NSAV
0.3$0.02-0.0%$129.95 millionN/A0.00News Coverage
Gap Down
Terra Tech logo
TRTC
Terra Tech
0.7$0.29-0.0%$63.02 million$28.05 million0.00News Coverage
General Cannabis logo
CANN
General Cannabis
0.6$0.89-0.0%$55.31 million$3.67 million0.00
PVSP
Pervasip
0.4$0.01-0.0%$45.10 millionN/A0.00Gap Up
Grow Capital logo
GRWC
Grow Capital
0.6$1.13-2.7%$28.07 million$2.37 million0.00News Coverage
Gap Up
NMUS
Nemus Bioscience
0.6$0.12-0.0%$16.07 millionN/A0.00High Trading Volume
Leafbuyer Technologies logo
LBUY
Leafbuyer Technologies
0.5$0.16-0.0%$13.70 million$2.53 million0.00Gap Down
MassRoots logo
MSRT
MassRoots
0.6$0.02-0.0%$11.16 million$20,000.000.00Gap Up
Peak Pharmaceuticals logo
PKPH
Peak Pharmaceuticals
0.7$0.14-0.0%$10.59 millionN/A0.00News Coverage
Mentor Capital logo
MNTR
Mentor Capital
0.5$0.16-5.1%$3.83 million$4.33 million-3.99
FutureWorld logo
FWDG
FutureWorld
0.5$0.00-0.0%$3.80 millionN/A0.00Gap Up
DIGP
DigiPath
0.5$0.05-0.2%$3.35 million$2.55 million-1.66Gap Up
NGBL
Notis Global
0.5$0.00-0.0%$2.50 millionN/A0.00Gap Up
United Cannabis logo
CNAB
United Cannabis
0.4$0.02-0.0%$1.70 millionN/A0.00
CrowdGather logo
CRWG
CrowdGather
0.7$0.01-0.0%$1.68 million$160,000.000.00News Coverage
Gap Up
OPMZ
1PM Industries
0.4$0.00-0.0%$0.00N/A0.00
AQSP
Acquired Sales
0.4$7.70-0.0%$0.00N/A0.00
AMMJ
American Cannabis
0.5$0.23-4.4%$0.00N/A0.00Gap Up
AmeriCann logo
ACAN
AmeriCann
0.4$1.21-5.0%$0.00N/A0.00Gap Down
Cannabis Sativa logo
CBDS
Cannabis Sativa
0.5$0.78-6.4%$0.00N/A0.00Gap Up
FRLF
Freedom Leaf
0.5$0.01-0.0%$0.00N/A0.00Gap Up
FUTL
FutureLand
0.4$0.00-0.0%$0.00N/A0.00News Coverage
Gap Up
GB Sciences logo
GBLX
GB Sciences
0.5$0.06-0.0%$0.00N/A0.00News Coverage
Gap Down
GreenGro Technologies logo
GRNH
GreenGro Technologies
0.6$0.02-0.0%$0.00N/A0.00Gap Down
Harvest Health & Recreation logo
HRVSF
Harvest Health & Recreation
1.3$3.06-2.0%$0.00N/A0.00
Marijuana Company of America logo
MCOA
Marijuana Company of America
0.5$0.01-0.0%$0.00N/A0.00News Coverage
Gap Down
Medical Marijuana logo
MJNA
Medical Marijuana
0.6$0.06-0.0%$0.00N/A0.00Gap Down
Medican Enterprises logo
MDCN
Medican Enterprises
0.5$0.00-0.0%$0.00N/A0.00Gap Up
MDCL
Medicine Man Technologies
0.5$2.22-1.4%$0.00N/A0.00
NCAP
Northsight Capital
0.5$0.00-0.0%$0.00N/A0.00
OWC Pharmaceutical Research logo
OWCP
OWC Pharmaceutical Research
0.6$0.01-1.7%$0.00N/A0.00Gap Up
Surna logo
SRNA
Surna
0.6$0.07-2.0%$0.00N/A0.00
Ultrack Systems logo
MJLB
Ultrack Systems
0.6$0.09-10.7%$0.00N/A0.00Gap Down
BUDZ
WEED
0.6$0.59-0.0%$0.00N/A0.00Gap Up
Zoned Properties logo
ZDPY
Zoned Properties
0.6$0.65-6.2%$0.00N/A0.00Gap Up
ZZLL
ZZLL Information Technology
0.4$0.32-57.2%$0.00N/A0.00High Trading Volume
Gap Down
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.